NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 85 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 265 | 0.0% | 0.00% | – |
| Q2 2023 | $1 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -100.0% | 265 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 265 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -20.0% | 265 | 0.0% | 0.00% | – |
| Q4 2021 | $5,000 | -16.7% | 265 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | +100.0% | 265 | +81.5% | 0.00% | – |
| Q2 2021 | $3,000 | -25.0% | 146 | 0.0% | 0.00% | – |
| Q1 2021 | $4,000 | 0.0% | 146 | +12.3% | 0.00% | – |
| Q4 2020 | $4,000 | -33.3% | 130 | -65.4% | 0.00% | – |
| Q3 2020 | $6,000 | +20.0% | 376 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | 0.0% | 376 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -28.6% | 376 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |